Since 1990, Questcor Pharmaceuticals, Inc. has remained focused on developing specialty pharmaceutical products aimed at treating patients with inflammatory and autoimmune disorders that are severe and challenging to treat. The company’s main pharmaceutical product is Acthar which is approved for the management of infantile spasms: an uncommon and dangerous form of epilepsy that usually starts during the first year after birth. In 2001, when the firm acquired the drug from Sanofi-Aventis, it sold it for forty dollars a vial, a year later the drug was at fifteen hundred dollars; in 2013, the price hiked to 28,000 dollars per vial. After the company had been purchased by Mallinckrodt Pharmaceuticals in 2014, the price per vial rose to 34,000 dollars (Crew, 2017). In this respect, the price is in a level which prevents a significant amount of consumers to purchase the products. Thus, for Questcor to successfully remain competitive in price and to expand the drug’s market, it should focus on research and development in both developing for other uses of Acthar and seeking for more substitutions.

Recommendations: Research and Development
As of data released by the company for the first quarter of fiscal year 2017, the total assets …show more content…
This will include costs incurred on salaries and wages of personnel, costs of consumed materials and services, depreciation of equipment and facilities used in the studies such as those in the laboratory, overhead costs, and other costs such as paying off licenses and patents. It will require additional $100 million in sensitizing the public about its findings so that the patients requiring the drug are aware and this will enlarge the market. The total budget will be satisfied with the net income shown in